Teva Specialty Product Pipeline
by development stage - March 2020
Teva specialty pipeline by development stage, excluding country / regional launches of products submitted or under review in new markets.
*Visit https://www.tevausa.com/our-products/article-pages/Specialty-Medicines-List/ for full prescribing information for these products in the US.
Pipeline is current as of March 2020
1) These uses are investigational. Fremanezumab is approved in the United States for another indication as AJOVY ® (fremanezumab-vfrm) injection*
2) In partnership with Regeneron
3) These uses are investigational. Deutetrabenazine is approved in the United States for other indications as AUSTEDO® (deutetrabenazine) tablets*